Litfulo
Ritlecitinib · U.S. Pharmaceuticals
CANCER MEDICINE · PRESCRIPTION ONLY (USA)Litfulo ingredients
| Active ingredient | Strength |
|---|---|
| Ritlecitinib Tosylate | 50 mg/1 |
What Litfulo is used for
Litfulo is a cancer medicine (kinase inhibitor). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Litfulo
- Generic name
- Ritlecitinib
- Made by
- U.S. Pharmaceuticals
- Forms
- Capsule
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA215830
- On the US market since
- 2023
Official information
- Litfulo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ritlecitinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Litfulo?
Litfulo (Ritlecitinib) is a cancer medicine made by U.S. Pharmaceuticals, approved by the US FDA.
What are the ingredients of Litfulo?
Litfulo contains Ritlecitinib Tosylate (50 mg/1).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA